Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries

Talbird, Sandra; Taylor, Thomas N.; Knoll, S.; Frostad, Carl Richard; Martí, Sebastián García

doi:10.1016/j.vaccine.2010.06.016

Cited by 29 publications

(29 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This article was the same for both searches and was included in the review [7]. In total, 16 articles were included in the final analysis (Table 1) [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22].…”

Section: Literature Search Resultsmentioning

confidence: 99%

“…One study included nine-valent PCV (an unmarketed vaccine [20]), two compared PCV10 with PCV7 [8,13], and one compared PCV13 with PCV7 [11]. Seven were cohort-based models [15][16][17][18][19][20][21], nine studies used some variation of a population-based model [7][8][9][10][11][12][13][14]22], and most were from the healthcare perspective (Table 1).…”

Section: Model Comparisonsmentioning

confidence: 99%

“…The epidemiologic data used in the analyses, specifically serotype coverage, and disease incidence, were variable across studies (Table 2) [3,5,[7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26]. Serotype coverage was either taken from a time period prior to widespread PCV7 use or the most current serotype coverage data were utilized.…”

Section: Model Comparisonsmentioning

confidence: 99%

“…One analysis [22] used Israeli nasopharyngeal carriage (NPC) data as a proxy for AOM etiology. Four analyses [7,13,17,18], used the distribution of serotypes taken from a meta-analysis of pneumococcal isolates collected from 1994 to 2000 [27] as a proxy for local representation of current AOM etiology. And finally, two studies obtained data from a local study where the etiology of AOM cases had been examined [8,15].…”

Section: Model Comparisonsmentioning

confidence: 99%

“…All models including PCV10 and PCV13 apply the selected value to the extent of serotype coverage in the newer vaccines to account for the impact of broader serotype coverage. Overall, 15 of 16 papers only included invasive disease caused by S. pneumoniae [7][8][9][10][11][12][13][14][15][16][17][19][20][21][22], whereas Knerer et al also included invasive disease caused by NTHi [18]. In this analysis, the efficacy of PCV10 against NTHi invasive disease was assumed to be equivalent to the efficacy against AOM caused by NTHi, estimated from the POET study using PCV11 [5,18].…”

Section: Model Comparisonsmentioning

confidence: 99%

See 4 more Smart Citations

Cost–effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions

Farkouh

Klok

Postma

et al. 2012

Expert Review of Vaccines

View full text Add to dashboard Cite

Section: Literature Search Resultsmentioning

confidence: 99%

Section: Model Comparisonsmentioning

confidence: 99%

Section: Model Comparisonsmentioning

confidence: 99%

Section: Model Comparisonsmentioning

confidence: 99%

Section: Model Comparisonsmentioning

confidence: 99%

See 3 more Smart Citations

Cost–effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions

Farkouh

Klok

Postma

et al. 2012

Expert Review of Vaccines

View full text Add to dashboard Cite

Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children

Shiragami

Mizukami

Leeuwenkamp³

et al. 2014

Infect Dis Ther

View full text Add to dashboard Cite

IntroductionDiseases caused by Streptococcus pneumoniae represent a major public health problem. The purpose of this study was to compare, in the Japanese context, the projected health benefits, costs and cost-effectiveness of the latest generation of pneumococcal conjugate vaccines which may provide important insight into the potential public health impact of interventions in the context of local disease-specific epidemiology.MethodsA Markov model was used to compare two vaccination strategies which involve routine infant immunization with either the 13-valent pneumococcal conjugate vaccine (PCV-13; Prevenar 13™, Pfizer, Pearl River, NY, USA) or the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV; Synflorix™, GlaxoSmithKline Biologicals SA, Rixensart, Belgium) over a time horizon of 5 years from the healthcare provider and societal perspectives. Estimates for key model parameters were obtained from locally available databases and published literature. Incremental benefits in terms of costs and quality-adjusted life-year and cost-effectiveness were assessed.ResultsA 3 + 1 vaccination schedule for infants with PHiD-CV is expected to have a similar impact on invasive pneumococcal disease and pneumonia and a larger impact on acute otitis media-related outcomes compared with PCV-13. Assuming price parity for these vaccines, the model projected that vaccination with PHiD-CV would result in cost savings of 1.9 and 3.9 billion Japanese yen from the provider and societal perspectives, respectively. This was largely due to a reduction in highly prevalent acute otitis media. Vaccination with PHiD-CV was expected to generate a gain of 433 quality-adjusted life-years compared to PCV-13 translating into dominance over PCV-13. Sensitivity analyses showed robustness of model outcome to changes in key model parameters and substantiated that the model outcome was consistently driven by the incremental benefit of PHiD-CV in averting acute otitis media.ConclusionIn comparison to PCV-13, vaccination with PHiD-CV is projected to be cost saving for Japan from both the healthcare provider and societal perspectives.Electronic supplementary materialThe online version of this article (doi:10.1007/s40121-014-0053-7) contains supplementary material, which is available to authorized users.

show abstract

Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis

Ta,

Kühne,

Laurenz

et al. 2024

Infect Dis Ther

View full text Add to dashboard Cite

Introduction Since 2009, a pneumococcal conjugate vaccine (PCV) covering 13 serotypes (PCV13) has been included by Germany’s Standing Committee on Vaccinations for infants, resulting in major reductions in pneumococcal disease (PD). Higher-valent vaccines may further reduce PD burden. This cost-effectiveness analysis compared 20-valent PCV (PCV20) under a 3+1 schedule with 15-valent PCV (PCV15) and PCV13, both under 2+1 schedule, in Germany’s pediatric population. Methods A Markov model with annual cycles over a 10-year time horizon was adapted to simulate the clinical and economic impact of pediatric vaccination with PCV20 versus lower-valent PCVs in Germany. The model used PCV13 clinical effectiveness and impact studies as well as PCV7 efficacy studies for vaccine direct and indirect effect estimates. Epidemiologic, utility, and medical cost inputs were obtained from published sources. Benefits and costs were discounted at 3% from a German societal perspective. Outcomes included PD cases, deaths, costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). Results In the base case, PCV20 provided greater health benefits than PCV13, averting more cases of invasive pneumococcal disease (IPD; 15,301), hospitalized and non-hospitalized pneumonia (460,197 and 472,365, respectively), otitis media (531,634), and 59,265 deaths over 10 years. This resulted in 904,854 additional QALYs and a total cost saving of €2,393,263,611, making PCV20 a dominant strategy compared with PCV13. Compared to PCV15, PCV20 was estimated to avert an additional 11,334 IPD, 704,948 pneumonia, and 441,643 otitis media cases, as well as 41,596 deaths. PCV20 was associated with a higher QALY gain and lower cost (i.e., dominance) compared with PCV15. The robustness of the results was confirmed through scenario analyses as well as deterministic and probabilistic sensitivity analyses. Conclusion PCV20 3+1 dominated both PCV13 2+1 and PCV15 2+1 over 10 years. Replacing lower-valent PCVs with PCV20 would result in greater clinical and economic benefits, given PCV20’s broader serotype coverage. Supplementary Information The online version contains supplementary material available at 10.1007/s40121-024-00977-4.

show abstract

Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries

Cited by 29 publications

References 22 publications

Cost–effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions

Cost–effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions

Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children

Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis

Contact Info

Product

Resources

About